▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 28, 2024

Bio

Dong-A ST aims for W50b revenue on Suganon sales hike

  • PUBLISHED :January 14, 2019 - 16:09
  • UPDATED :January 14, 2019 - 16:09
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Korean pharmaceutical company Dong-A ST announced on Jan. 14 that it aims to expand its ethical drug division by stepping up sales of Suganon.

“We are hoping for Suganon’s sales to hit 50 billion won (US$ 44.52 million),” a Dong-A ST spokesperson told The Investor, while declining to reveal the target date.




Suganon is a new diabetes treatment that the drug maker developed in March 2016, which has been showing rapid sales growth in the last few years. Its sales from January to November last year surged 30 percent compared to the previous year to 8.6 billion won.

The Korean company also plans to further cooperate with CJ HealthCare, the pharmaceutical arm of CJ Group, which signed a contract in April 2018 to work together in selling and marketing Suganon, to increase its market share here.

“We will also expand our presence overseas with Suganon, having already exported the tech to around 25 countries including China, India, Russia and Brazil,” the company spokesperson added.

The decision to bolster its new drug portfolio came after the company experienced some limitations in selling generic medicines as its contracts with global medicine firms expires.

Additionally, some industry watchers say that as the company experienced some potential risks last year it led Dong-A ST to actively search for a new growth engine. The Korean government ordered a price cut on some 130 items produced by the pharmaceutical company for having dished out illegal rebates. A final decision on the price cut has not been made yet.

By Song Seung-hyun (ssh@heraldcorp.com)

EDITOR'S PICKS